AlphaBiomics
AlphaBiomics creates precision medicine solutions based on people's microbiomes. Their first product, RxSelex™, is a microbiome-based predictive diagnostic tool for patients with inflammatory bowel disease (IBD). From the comfort of their home, patients can send a stool sample, which the RxSelex™ algorithm will then analyse and support doctors to make informed decisions about the best drug treatment for that particular patient.
We supported AlphaBiomics in developing a go-to-market strategy to bring RxSelex™ to healthcare systems like the NHS.
XXX
What they needed
As a startup in the early stages of product development, the founders of AlphaBiomics sought help from Hardian to develop a go-to-market strategy, to minimise risk and optimise their chances of success and adoption into healthcare systems like the NHS. The founding team, who all have academic backgrounds, acknowledged their gap in skill set in developing a business model for RxSelex™.
Who are they?
Anthony Williamson,
Co-founder and CEO, AlphaBiomics:
“We knew that there were gaps in our thinking and gaps in our skill sets in terms of pulling a very holistic and solid go-to-market strategy together. That, I think, is what we've been able to achieve with Hardian.”
“We knew that there were gaps in our thinking and gaps in our skill sets in terms of pulling a very holistic and solid go-to-market strategy together. That, I think, is what we've been able to achieve with Hardian.”
Anthony Williamson,
Co-founder and CEO, AlphaBiomics:
How we helped
Our collaboration began with the Innovate UK Fast Start grant, which enabled us to work with the team on developing a GTM strategy. We conducted a thorough competitor analysis and provided market intelligence to bring clarity to RxSelex™'s position in the market. To establish RxSelex™ as an innovation that could be adopted by the NHS, our experts identified and interviewed individuals who understand the procurement landscape, gaining an understanding of the needs of key decision-makers and end users.
The result
AlphaBiomics went from a very rudimentary go-to-market strategy to a more convincing, holistic, fact-based go-to-market strategy. The team can now approach commercialisation with greater confidence, with a strategy that demonstrates to potential investors their ability to realise the potential of their innovative technology in a difficult and competitive ecosystem.